GoingToMeet

Predictive toxicology is the first step in developing any viable drug on the market. Toxicology testing has evolved greatly to incorporate the possibility of using alternatives to animal models and the application of biomarkers to evaluate adverse effects. There is also cutting-edge research into areas such as CNS and cardiovascular disease. By understanding technological advances in how to best use in vitro and in silico methods to better predict in vivo results, a company can cost effectively develop drugs that will ensure market survival. This 2nd annual marcus evans conference will provide valuable knowledge to enhance drug development strategies by profiling novel solutions for toxicology screening with the latest predictive tools. Attendees will receive key industry and regulatory insights on overcoming regulatory pressures in achieving approval on biomarker use for models and qualification of data on products. The use of outsourced contract research organisations (CROs) will be evaluated which in turn will provide analysis on minimising costs and improving data quality to ensure business success.